3SBio Inc Shs Unitary 144A/Reg S 01530
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 2.48B
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 4.25
- Price/Sales
- 2.11
- Dividend Yield (Trailing)
- 1.51%
- Dividend Yield (Forward)
- 1.51%
- Dividend Payment Schedule
- Aug
- Total Yield
- 1.51%
Company Profile
3SBio Inc is an investment holding company. It is a primary biotechnology company. The company is principally engaged in the development, production, marketing and sale of biopharmaceutical products in the People's Republic of China. The group has only one operating segment. It has presence in Chinese mainland, USA, Other countries/regions. The majority of revenue comes from USA. The core commercialized products of the group include several bio-pharmaceutical drugs, namely, TPIAO, recombinant human erythropoietin (rhEPO) products EPIAO and SEPO, Yisaipu and Cipterbin, and a small molecule drug, Mandi series of minoxidil drugs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 6,068
- Website
- https://www.3sbio.com
Valuation
|
Metric
|
01530
|
|---|---|
Price/Earnings (Normalized) | 4.25 |
Price/Book Value | 1.30 |
Price/Sales | 2.11 |
Price/Cash Flow | 3.94 |
Price/Earnings
01530
Financial Strength
|
Metric
|
01530
|
|---|---|
Quick Ratio | 5.70 |
Current Ratio | 6.06 |
Interest Coverage | 187.38 |
Quick Ratio
01530
Profitability
|
Metric
|
01530
|
|---|---|
Return on Assets (Normalized) | 35.55% |
Return on Equity (Normalized) | 47.87% |
Return on Invested Capital (Normalized) | 38.39% |
Return on Assets
01530
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|HDWFWY | LOCK|yKKkM | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@By&<@H | LOCK|cH<s | $76B | |||
| Moderna Inc
MRNA
| LOCK|^ZdwWl& | LOCK|^q& | $75B | |||
| argenx SE ADR
ARGX
| LOCK|Z?X<kr | LOCK|FH | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%!@W#> | LOCK|?v | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>Bf^#?$ | LOCK|^!hq | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Py!&l?R | LOCK|??<L> | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|V#vD?dN | LOCK|NZ | $24B | |||
| Incyte Corp
INCY
| LOCK|!y?jV%# | LOCK|??G | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|P@GQjR | LOCK|ZY | $15B |
United States